This is an amended filing · View original →
SAMSUNG BIOLOGICS CO.,LTD. [Amended] Single Sales/Supply Contract
SAI summary · Not investment advice
Samsung Biologics corrected the contract value of its contract manufacturing deal with a US pharmaceutical company to KRW 62.8 billion, or 8.95% of recent revenue.
Contract amount
KRW 62.8 billion
Key facts
- Contract details
- Pharmaceutical contract manufacturing agreement
- Recent revenue
- KRW 701.6 billion
- % of revenue
- 8.95%
- Counterparty
- A pharmaceutical company based in the United States
- Contract period
- 2020-10-28 to 2030-12-31
- Contract date
- Nov 3, 2020
- Payment terms
- No down payment or advance paymentNo down payment or advance payment
- Disclosure deferral
- Counterparty details withheld
Commentary
AI commentary · Not investment advice
What happened
Samsung Biologics disclosed a contract manufacturing agreement for pharmaceuticals with a U.S.-based drugmaker, and the filing corrects the contract amount to KRW 62.8 billion. The contract was signed on 2020.11.03 and runs from 2020-10-28 to 2030-12-31. The counterparty's name has been withheld from disclosure.
In the company's terms
Relative to the company, the contract amount equals 8.95% of its most recent revenue of KRW 701.6 billion. Against market capitalization, it is 0.1%. The company has made 6 disclosures of this type over the past year, with earlier ones dated 2026.10.02, 2026.09.10 and 2026.03.13.
What changes for shareholders
For shareholders, the filing states that the payment terms include no down payment or advance payment. The filing was received on 2026.11.02.
Earlier Single Sales/Supply Contract filings from this company
| Filed | Counterparty | Contract amount | % of revenue |
|---|---|---|---|
| 26.10.022026.10.02 | A European pharmaceutical company | KRW 93.5 billion | 2.05% |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist